We recently compiled a list of the 10 Best Cosmetic Surgery and Aesthetics Stocks To Buy. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other cosmetic surgery and aesthetics stocks.
While imperfections are inherent to being human, aesthetic (or cosmetic) plastic surgery is a viable alternative if self-consciousness and unhappiness over your appearance are causing you distress.
Estimated at $57.67 billion in 2023, the global cosmetic surgery market is expected to grow at a CAGR of 4.0% from $59.77 billion in 2024 to $81.66 billion by 2032, as per Fortune Business Insights. Regionally, North America dominated the market in 2023, with a market value of $18.10 billion.
Per the aforementioned research, the market is growing mainly because cosmetic procedures are becoming increasingly popular among people in general as a means of improving their visual appeal. Following the pandemic, when most individuals were attending virtual meetings and interacting on social media, there was a notable spike in cosmetic surgery. According to a 2023 study, there was an almost 30% rise in cosmetic procedures in 2021, compared to 2019, and a nearly 50% increase in 2020.
According to the annual Global Survey on Aesthetic/Cosmetic Procedures, in 2023, plastic surgeons performed over 15.8 million surgical procedures, up 5.5% from the previous year. There has been a 40% rise overall over the past four years. As per the survey, liposuction was the most prevalent surgical procedure in 2023 and 2022, with over 2.2 million carried out, followed by breast augmentation, eyelid surgery, abdominoplasty, and rhinoplasty. Botulinum toxin, hyaluronic acid, hair removal, non-surgical skin tightening, and non-surgical fat reduction were the most popular non-surgical procedures. All face and head operations rose by 19.6% over the previous year, totaling more than 6.5 million procedures.
According to Dan Yamini, M.D., a board-certified plastic surgeon at Visthetic Surgery Institute & Med Spa, the growing trend of minimally invasive procedures like injectables (such as fillers and neurotoxins) that enable people to address specific concerns and achieve subtle improvements without surgery is indicative of the desire for natural looks.
Top plastic surgeons debated and discussed the newest ideas and innovations in plastic surgery at this year’s American Society for Aesthetic Plastic Surgery (The Aesthetic Society) conference in Vancouver. Preservation rhinoplasty, which reshapes the nose while preserving its natural structure and provides a more nuanced approach than standard procedures, was a hot topic. While plastic surgeon Adam Rubinstein, MD, of Miami, believes it’s just a marketing word, Austin, Texas’s Adam Weinfeld, MD, appreciates its subtle approach.
Secondly, the buzz is also about GLP-1’s role in plastic surgery. GLP-1 medications, which were once developed to treat diabetes, are now used to reduce weight but a side effect of them is the sagging of the skin. Johnny Franco, MD, a plastic surgeon in Austin, Texas, states that after using GLP-1s to lose a large amount of weight, patients are now looking for remedies for sagging skin. They revealed that to address this, they provide surgical alternatives as well as skin-tightening therapies such as BodyTite and Renuvion. Conversely, the Delray Beach, FL, plastic surgeon Drew Schnitt, MD, warns against their long-term consequences. Extended stomach tucks are advised by New York plastic surgeon Mokhtar Asaadi, MD to tighten skin and muscles after weight loss.
GLP-1 drugs are all the rage in 2024 and the global weight loss drugs market is expected to reach $130 billion by 2030, as per estimates by JP Morgan Research. We covered this theme in our article about the 10 Best GLP-1 and Weight Loss Stocks to Buy Now. Here’s an excerpt from the article:
“Over the past ten years, the usage of GLP-1 drugs, such as semaglutide, for weight loss has doubled, but among those with type 2 diabetes, its use has decreased by almost 10%, according to research published on Monday in the Annals of Internal Medicine. The prolonged medication scarcity that followed, the researchers caution, may restrict the medications’ accessibility to those with diabetes. Dr. Yee Hui Yeo, a clinical fellow in the Karsh Division of Gastroenterology and Hepatology at Cedars-Sina, highlighted that as demand for obesity medications rises, it is critical to guarantee that diabetic patients have access to GLP-1 medicines.
The FDA claims that the shortages are the result of rising demand. Not only do the shortages impact the United States: The European Medicines Agency cautioned that the GLP-1 drug shortage is a “major public health concern” that is unlikely to be remedied in 2024. People with diabetes have struggled to obtain their prescriptions due to shortages, with some limiting their drugs to manage, according to NPR.”
Our Methodology
We sifted through online rankings and holdings of ETFs to form an initial list of 15 best cosmetic surgery and aesthetics stocks. Then we selected the 10 stocks that were the most popular among institutional investors. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
AbbVie Inc. (NYSE:ABBV)
Number of Hedge Fund Investors: 70
AbbVie Inc. (NYSE:ABBV) is a biopharmaceutical company that specializes in creating and distributing innovative treatments, which include dermatological and aesthetic products. For the treatment of wrinkles and volume loss in the face, the firm provides aesthetic treatments such as BOTOX Cosmetic and JUVÉDERM dermal fillers.
In July, Abbvie’s price target was increased by Truist Securities to $210 from $195, with a reiteration of a Buy rating following solid Q2 2024 results.
Abbvie’s aesthetics portfolio generated $1.39 billion in worldwide net revenues in the second quarter of 2024, up 0.5% from the same period the previous year. Juvederm brought in $343 million, while net sales from Botox Cosmetics were $729 million. By 2033, ABBV anticipates a double-digit CAGR in aesthetic medicine. Abbvie’s premier Botox product guarantees an impressive market share in the aesthetics market.
Polen Focus Growth Strategy stated the following regarding AbbVie Inc. (NYSE:ABBV) in its Q2 2024 investor letter:
“In the second quarter, the top relative contributors to the Portfolio’s performance were all names we do not hold: Home Depot, Meta Platforms, and AbbVie Inc. (NYSE:ABBV). AbbVie fell on the back of results that failed to allay concerns around continuing biosimilar threats to its very large, blockbuster arthritis drug, Humira, which went off patent last year.”
Although sales of Humira and Imbruvica may be impacted by the Inflation Reduction Act, Abbvie is anticipated to maintain long-term growth. The company presented its prospects for growth until the end of the decade, bolstered by its pipeline of innovative products and services. The optimistic forecast indicates faith in Abbvie’s capacity to overcome market obstacles and seize expansion opportunities.
BMO Capital Markets and JPMorgan also raised their price targets to $210 and $214, respectively. Abbvie surpassed market expectations with adjusted earnings per share of $2.65, achieving Q2 sales of $14.46 billion, up 4.31% from the same period the previous year. The company has named Dr. Roopal Thakkar as EVP of R&D and Chief Scientific Officer and is requesting FDA and EMA clearance for upadacitinib for giant cell arteritis, supported by encouraging findings from the Phase 3 SELECT-GCA research.
In the first quarter of 2024, 70 hedge funds out of 920 reported holding an ownership stake in AbbVie Inc. (NYSE:ABBV). Bernard Horn’s Polaris Capital Management is the largest shareholder in the company, with 234,479 shares worth $40.22 million.
Overall ABBV ranks 2nd on our list of the best cosmetic surgery and aesthetics stocks to buy. You can visit 10 Best Cosmetic Surgery and Aesthetics Stocks To Buy to see the other cosmetic surgery and aesthetic stocks that are on hedge funds’ radar. While we acknowledge the potential of ABBV as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Analyst Sees a New $25 Billion “Opportunity” for NVIDIA and Jim Cramer is Recommending These 10 Stocks in June.
Disclosure: None. This article is originally published at Insider Monkey.
